Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2024-06-24 Sale |
2024-07-08 4:30 pm |
GENELUX Corp | GNLX | Jewett Caroline Head of Quality |
4,961 | $2.12 | $10,517 | 16,174 (Direct) |
View |
| 2024-05-29 Purchase |
2024-06-07 9:45 pm |
GENELUX Corp | GNLX | Tyree James L Director |
6,250 | $0 | $0 | 15,960 (Direct) |
View |
| 2024-05-29 Purchase |
2024-06-07 9:45 pm |
GENELUX Corp | GNLX | Smither John W Director |
6,250 | $0 | $0 | 19,420 (Direct) |
View |
| 2024-05-29 Purchase |
2024-06-07 9:45 pm |
GENELUX Corp | GNLX | Thomas John Director |
2,500 | $0 | $0 | 468,460 (Direct) |
View |
| 2024-05-29 Purchase |
2024-06-07 9:45 pm |
GENELUX Corp | GNLX | Mirabelli Mary Director |
8,000 | $0 | $0 | 20,460 (Direct) |
View |
| 2024-05-29 Purchase |
2024-06-07 9:40 pm |
GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations |
2,500 | $0 | $0 | 5,000 (Direct) |
View |
| 2024-05-29 Purchase |
2024-06-07 9:40 pm |
GENELUX Corp | GNLX | Zindrick Thomas President and CEO |
200,000 | $0 | $0 | 414,651 (Indirect Direct) |
View |
| 2024-05-29 Purchase |
2024-06-07 9:40 pm |
GENELUX Corp | GNLX | Smalling Ralph Head of Regulatory |
1,250 | $0 | $0 | 14,565 (Direct) |
View |
| 2024-05-29 Purchase |
2024-06-07 9:40 pm |
GENELUX Corp | GNLX | Ryder Sean General Counsel |
10,000 | $0 | $0 | 20,572 (Direct) |
View |
| 2024-05-29 Purchase |
2024-06-07 9:40 pm |
GENELUX Corp | GNLX | Zak Lourie S. Chief Financial Officer |
31,250 | $0 | $0 | 62,500 (Direct) |
View |
| 2024-05-13 Sale |
2024-05-15 5:59 pm |
GENELUX Corp | GNLX | Szalay Aladar 10% Owner |
35,966 | $3.625 | $130,377 | 3,953,581 (Indirect) |
View |
| 2024-05-07 Sale |
2024-05-09 4:38 pm |
GENELUX Corp | GNLX | Szalay Aladar 10% Owner |
19,944 | $3.7756 | $75,300 | 3,989,547 (Indirect) |
View |
| 2024-04-29 Sale |
2024-05-01 6:16 pm |
GENELUX Corp | GNLX | Szalay Aladar 10% Owner |
59,999 | $3.2323 | $193,934 | 4,009,491 (Indirect) |
View |
| 2024-04-22 Sale |
2024-04-24 5:50 pm |
GENELUX Corp | GNLX | Szalay Aladar 10% Owner |
44,395 | $3.506 | $155,647 | 4,069,490 (Indirect) |
View |
| 2024-04-16 Sale |
2024-04-18 5:00 pm |
GENELUX Corp | GNLX | Szalay Aladar 10% Owner |
71,420 | $3.5876 | $256,227 | 4,113,885 (Indirect) |
View |
| 2023-12-15 Sale |
2023-12-18 4:15 pm |
GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations |
32,535 | $13.16 | $428,180 | 0 (Direct) |
View |
| 2023-12-13 Sale |
2023-12-14 8:59 pm |
GENELUX Corp | GNLX | Tyree James L Director |
9,000 | $13.22 | $118,969 | 3,460 (Direct) |
View |
| 2023-12-13 Sale |
2023-12-14 8:58 pm |
GENELUX Corp | GNLX | Thomas John Director |
9,000 | $13.38 | $120,387 | 463,460 (Direct) |
View |
| 2023-12-07 Sale |
2023-12-08 5:57 pm |
GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations |
36,800 | $11.85 | $435,995 | 32,535 (Direct) |
View |
| 2023-11-21 Sale |
2023-11-22 4:15 pm |
GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations |
18,665 | $10.26 | $191,555 | 69,335 (Direct) |
View |
| 2023-11-17 Sale |
2023-11-21 4:15 pm |
GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations |
18,135 | $11.6 | $210,431 | 88,000 (Direct) |
View |
| 2023-10-25 Sale |
2023-10-26 5:07 pm |
GENELUX Corp | GNLX | Szalay Aladar 10% Owner |
5,704 | $19.4 | $110,638 | 4,185,305 (Indirect) |
View |
| 2023-10-23 Sale |
2023-10-25 4:51 pm |
GENELUX Corp | GNLX | Szalay Aladar 10% Owner |
49,987 | $19.97 | $998,365 | 4,191,009 (Indirect) |
View |
| 2023-10-24 Sale |
2023-10-25 4:15 pm |
GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations |
5,200 | $19.11 | $99,351 | 313,788 (Direct) |
View |
| 2023-10-16 Sale |
2023-10-16 6:39 pm |
GENELUX Corp | GNLX | Thomas John Director |
3,333 | $20.71 | $69,038 | 472,460 (Direct) |
View |
| 2023-10-10 Sale |
2023-10-11 4:10 pm |
GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations |
5,200 | $22.01 | $114,462 | 318,988 (Direct) |
View |
| 2023-10-05 Sale |
2023-10-10 4:49 pm |
GENELUX Corp | GNLX | Szalay Aladar 10% Owner |
14,251 | $24.93 | $355,229 | 4,240,996 (Indirect) |
View |
| 2023-10-03 Sale |
2023-10-04 6:43 pm |
GENELUX Corp | GNLX | Szalay Aladar 10% Owner |
75,690 | $25.49 | $1,929,225 | 4,255,247 (Indirect) |
View |
| 2023-09-27 Sale |
2023-09-29 4:34 pm |
GENELUX Corp | GNLX | Szalay Aladar 10% Owner |
13,546 | $24.41 | $330,669 | 4,330,937 (Indirect) |
View |
| 2023-09-25 Sale |
2023-09-27 4:33 pm |
GENELUX Corp | GNLX | Szalay Aladar 10% Owner |
42,263 | $24.38 | $1,030,181 | 4,344,483 (Indirect) |
View |
| 2023-09-26 Sale |
2023-09-27 4:10 pm |
GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations |
5,200 | $23.56 | $122,528 | 324,188 (Direct) |
View |
| 2023-09-21 Sale |
2023-09-25 6:30 pm |
GENELUX Corp | GNLX | Szalay Aladar 10% Owner |
16,591 | $27.85 | $462,001 | 4,386,746 (Indirect) |
View |
| 2023-09-20 Sale |
2023-09-21 4:35 pm |
GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations |
6,000 | $27.96 | $167,786 | 329,388 (Direct) |
View |
| 2023-09-20 Sale |
2023-09-21 4:30 pm |
GENELUX Corp | GNLX | Ryder Sean General Counsel |
10,000 | $30 | $300,000 | 140,572 (Direct) |
View |
| 2023-09-18 Sale |
2023-09-20 4:48 pm |
GENELUX Corp | GNLX | Szalay Aladar 10% Owner |
62,459 | $24.92 | $1,556,591 | 4,403,337 (Indirect Direct) |
View |
| 2023-09-15 Sale |
2023-09-18 8:13 pm |
GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations |
10,400 | $21.89 | $227,630 | 335,388 (Direct) |
View |
| 2023-09-15 Sale |
2023-09-18 8:12 pm |
GENELUX Corp | GNLX | Thomas John Director |
6,667 | $23.45 | $156,313 | 475,793 (Direct) |
View |
| 2023-09-13 Sale |
2023-09-15 8:06 pm |
GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations |
29,800 | $21.14 | $629,927 | 106,135 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2024-02-19 Option Award |
2024-07-08 4:30 pm |
N/A N/A |
GENELUX Corp | GNLX | Jewett Caroline Head of Quality |
4,755 | $0 | 16,174 (Direct) |
View |
| 2023-10-24 Exercise |
2023-10-25 4:15 pm |
N/A 2029-09-20 |
GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations |
5,200 | $0 | 313,788 (Direct) |
View |
| 2023-10-24 Exercise |
2023-10-25 4:15 pm |
N/A N/A |
GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations |
5,200 | $6 | 313,788 (Direct) |
View |
| 2023-10-10 Exercise |
2023-10-11 4:10 pm |
N/A 2029-09-20 |
GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations |
5,200 | $0 | 318,988 (Direct) |
View |
| 2023-10-10 Exercise |
2023-10-11 4:10 pm |
N/A N/A |
GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations |
5,200 | $6 | 318,988 (Direct) |
View |
| 2023-10-02 Option Award |
2023-10-04 4:10 pm |
N/A 2033-10-01 |
GENELUX Corp | GNLX | Jewett Caroline Head of Quality |
22,000 | $0 | 22,000 (Direct) |
View |
| 2023-09-26 Exercise |
2023-09-27 4:10 pm |
N/A 2029-09-20 |
GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations |
5,200 | $0 | 324,188 (Direct) |
View |
| 2023-09-26 Exercise |
2023-09-27 4:10 pm |
N/A N/A |
GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations |
5,200 | $6 | 324,188 (Direct) |
View |
| 2023-09-20 Exercise |
2023-09-21 4:35 pm |
N/A 2029-09-20 |
GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations |
6,000 | $0 | 329,388 (Direct) |
View |
| 2023-09-20 Exercise |
2023-09-21 4:35 pm |
N/A N/A |
GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations |
6,000 | $6 | 329,388 (Direct) |
View |
| 2023-09-20 Exercise |
2023-09-21 4:30 pm |
N/A 2031-10-03 |
GENELUX Corp | GNLX | Ryder Sean General Counsel |
10,000 | $0 | 140,572 (Direct) |
View |
| 2023-09-20 Exercise |
2023-09-21 4:30 pm |
N/A N/A |
GENELUX Corp | GNLX | Ryder Sean General Counsel |
10,000 | $6 | 140,572 (Direct) |
View |
| 2023-09-15 Exercise |
2023-09-18 8:13 pm |
N/A 2029-09-20 |
GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations |
10,400 | $0 | 335,388 (Direct) |
View |
| 2023-09-15 Exercise |
2023-09-18 8:13 pm |
N/A N/A |
GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations |
10,400 | $6 | 335,388 (Direct) |
View |
| 2023-09-11 Option Award |
2023-09-15 8:06 pm |
N/A 2033-09-10 |
GENELUX Corp | GNLX | Zindrick Thomas President and CEO |
250,000 | $0 | 250,000 (Direct) |
View |